Key result
Magnetic resonance angiography demonstrated marked reduction in neovascularity in all 6 chemotherapy responders and persistent or increased neovascularity in all 3 non-responders.
Why the study?
Does magnetic resonance angiography (MRA) accurately assess neovascularity and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma?
Observational (n=9)
Does magnetic resonance angiography (MRA) accurately assess neovascularity and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma?
MRA can non-invasively assess tumoral neovascularity in vivo and monitor response to chemotherapy in patients with osteogenic or Ewing sarcoma.
This is the authors' abstract. We don't add key points for this paper.
Histologic studies on resected specimen have shown that tumor neovascularity is related to prognosis and response to therapy in a variety of human neoplasms. In nine patients with osteogenic or Ewing sarcoma, we evaluated the use of magnetic resonance angiography (MRA) to assess neovascularity non-invasively in vivo and to monitor response to chemotherapy. Seven patients with osteosarcoma and two patients with Ewing sarcoma were studied before and after chemotherapy by MRA (2-D time-of-flight gradient-echo sequence, TR = 50 msec, TE = 9.5 msec, theta = 50 degrees, acquisition time 13 min). MR angiograms were assessed for chemotherapy-induced changes in neovascularity. MRA showed both feeder vessels and neovascularity. Six patients responded to chemotherapy ( > or = 90% histologic tumor necrosis). MRA demonstrated marked reduction in neovascularity in all responders. Three patients did not respond to chemotherapy ( < 90% histologic tumor necrosis). MRA demonstrated persistent or increased neovascularity in the non-responders. MRA provides a unique opportunity to study tumoral neovascularity noninvasively in vivo and helps to assess response to chemotherapy in patients with osteogenic or Ewing sarcoma. These general principles may be applicable to other human tumors.
Answers are grounded in this paper and cite their sources.
MRA may noninvasively track sarcoma chemotherapy response; leaves open larger validation before routine use.
No takes yet. Share an insight, caveat, or question.
Lang et al. (1996) conducted an observational in Osteogenic or Ewing sarcoma (n=9). Magnetic resonance angiography (MRA) was evaluated on Chemotherapy-induced changes in neovascularity compared to histologic tumor necrosis. Magnetic resonance angiography demonstrated marked reduction in neovascularity in all 6 chemotherapy responders and persistent or increased neovascularity in all 3 non-responders.
Synapse has enriched 10 related papers. Consider them for comparative context: